

EMA/460851/2017

European Medicines Agency decision

P/0206/2017

of 9 August 2017

on the acceptance of a modification of an agreed paediatric investigation plan for semaglutide (EMEA-001441-PIP02-15-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0206/2017

of 9 August 2017

on the acceptance of a modification of an agreed paediatric investigation plan for semaglutide (EMA-001441-PIP02-15-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0217/2016 issued on 12 August 2016,

Having regard to the application submitted by Novo Nordisk on 24 March 2017 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 June 2017, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for semaglutide, tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novo Nordisk, Vandtaarnsvej 108-110, 2860 - Soeborg, Denmark.

EMA/PDCO/224418/2017

London, 23 June 2017

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-001441-PIP02-15-M01

Scope of the application

Active substance(s):

Semaglutide

Condition(s):

Treatment of type 2 diabetes mellitus

Pharmaceutical form(s):

Tablet

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Novo Nordisk

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novo Nordisk submitted to the European Medicines Agency on 24 March 2017 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0217/2016 issued on 12 August 2016.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 25 April 2017.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of type 2 diabetes mellitus

The waiver applies to:

- the paediatric population from birth to less than 10 years;
- tablet, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of type 2 diabetes mellitus

2.1.1. Indication(s) targeted by the PIP

Treatment of type 2 diabetes mellitus

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 10 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	5	Study 1 <i>(This study is the same as study 1 (14725-070) of semaglutide EMEA-001441-PIP01-13 for the SC formulation, P/0095/2015 of 8 May 2015 and subsequent modifications thereof).</i> In vitro binding study to evaluate the potency of GLP-1 agonists semaglutide, exenatide and liraglutide on the rat GPL-1 receptor.

Area	Number of measures	Description
		Study 2 <i>(This study is the same as study 2 (214276) of semaglutide EMEA-001441-PIP01-13 for the SC formulation, P/0095/2015 of 8 May 2015 and subsequent modifications thereof).</i> Dose range-finding juvenile toxicity study to evaluate the influence of daily subcutaneous administration of semaglutide on the developing organism. Study 3 <i>(This study is the same as study 3 (214479) of semaglutide EMEA-001441-PIP01-13 for the SC formulation, P/0095/2015 of 8 May 2015 and subsequent modifications thereof).</i> Definitive juvenile toxicity study in the rat to evaluate the influence of daily subcutaneous administration of semaglutide on the developing organism. Study 4 Exploratory toxicity study with the excipient SNAC only. To assess the toxicity of SNAC and its possible subclinical effects on non-standard biochemical and morphological parameters after 13 weeks repeat dosing to Sprague-Dawley (CD) rats. Study 5 Carcinogenicity study with the excipient SNAC only. To assess the carcinogenic potential and toxicokinetics of SNAC, an oral absorption enhancer, when administered orally to Sprague-Dawley rats for up to 104 weeks.
Clinical studies	1	Study 6 Randomised, 52-week, double-blind, parallel-group, placebo-controlled trial to evaluate the efficacy, safety and pharmacokinetics of semaglutide in paediatric patients from 10 to less than 18 years of age with type 2 diabetes mellitus as adjunct to diet and exercise and metformin, with or without concomitant basal insulin or diet and exercise and basal insulin alone.
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes